GcMAF and NaGalase: A novel immune treatment
Biomechanisms of the immune disrupter, NaGalase
An examination of the biomechanisms of NaGalase.
This compound is produced by cancer cells and viruses and prevents the activation of macrophages.
A way has been discovered to bypass the NaGalase enzyme and preliminary studies have shown surprising clinical success in the treatment of cancer.
It is thought these treatments may be effective in treating vaccine induced brain damage. A number of doctors have reported success.
Click here to read the abstract of the study, published in 2005 in the journal, "Microbes and Infection."
This compound is produced by cancer cells and viruses and prevents the activation of macrophages.
A way has been discovered to bypass the NaGalase enzyme and preliminary studies have shown surprising clinical success in the treatment of cancer.
It is thought these treatments may be effective in treating vaccine induced brain damage. A number of doctors have reported success.
Click here to read the abstract of the study, published in 2005 in the journal, "Microbes and Infection."
Treating advanced cancer with GcMAF: A series of case studies
A novel cancer treatment demonstrates success in clinical trials with advanced stage cancer patients. Here is a collection of case studies. These treatments have also showed promise in treating vaccine induced brain damage, aka autism.
Click here to read the entire study, written by the doctors involved, published in August, 2013 in the journal, "OncoImmunology."
Click here to read the entire study, written by the doctors involved, published in August, 2013 in the journal, "OncoImmunology."
Intrigue and science: The first study of NaGalase and the dying doctors
A slew of doctors have recently been killed (summer, 2015). What they all had in common was that they were studying the relationship between NaGalase, Gc Protein and autism and cancer.
In particular, Dr. Bradstreet, one of the most well known of the doctors, was successfully treating autistic children who were found to have high levels of NaGalase, a compound usually only found in those with cancer or active viral infections. Dr. Bradstreet was under the impression that the NaGalase was introduced into the body in infancy and claimed a 15% cure rate of autism and an 85% positive response rate through the use of Gc protein to reverse its effects.
The earliest study published in the peer reviewed, professional literature I could find on this relationship was published in the June, 1997 issue of the journal, "Cancer Research" by Dr. Nobuto Yamamoto of the Laboratory of Cancer Immunology and Molecular Biology at Albert Einstein Cancer Center.
"Four administrations to mice with 4 day intervals showed an extended survival of at least 90 days and an insignificantly low serum NaGalase level between days 30 and 90."
In essence, they cured the mice of cancer. Untreated mice died in about two weeks.
Click here to read the entire study by researchers in the Laboratory of Cancer Immunology and Molecular Biology, Albert Einstein Cancer Center, Philadelphia, Pennsylvania. It was published in June, 1997 in the journal, "Cancer Research."
In particular, Dr. Bradstreet, one of the most well known of the doctors, was successfully treating autistic children who were found to have high levels of NaGalase, a compound usually only found in those with cancer or active viral infections. Dr. Bradstreet was under the impression that the NaGalase was introduced into the body in infancy and claimed a 15% cure rate of autism and an 85% positive response rate through the use of Gc protein to reverse its effects.
The earliest study published in the peer reviewed, professional literature I could find on this relationship was published in the June, 1997 issue of the journal, "Cancer Research" by Dr. Nobuto Yamamoto of the Laboratory of Cancer Immunology and Molecular Biology at Albert Einstein Cancer Center.
"Four administrations to mice with 4 day intervals showed an extended survival of at least 90 days and an insignificantly low serum NaGalase level between days 30 and 90."
In essence, they cured the mice of cancer. Untreated mice died in about two weeks.
Click here to read the entire study by researchers in the Laboratory of Cancer Immunology and Molecular Biology, Albert Einstein Cancer Center, Philadelphia, Pennsylvania. It was published in June, 1997 in the journal, "Cancer Research."